Clinical trials: multiple sclerosis
Secondary Progressive Multiple Sclerosis
Acceptance Based Telephone Support When Transitioning to SPMS
What is the purpose of the study? People with Multiple Sclerosis often say that they feel less support is available after they are diagnosed with Secondary Progressive Multiple Sclerosis, compared to before they received this…
- Trial name
- AT-SPMS (NCT04239664)
- Testing
- Acceptance Based Telephone Support (ABS+UC)
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- University of Nottingham
Multiple Sclerosis (MS), Cerebral Small Vessel Diseases
MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis
This study investigates whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can improve the differentiation of white matter lesions in people aged 50-70 years with multiple sclerosis (MS).
- Trial name
- NCT07444047
- Where
- Norway
- Volunteers
- 1,000 people
- Sponsor
- Oslo University Hospital
Systemic Sclerosis
Exercise in People With Systemic Sclerosis
Raynaud's phenomenon and digital ulceration are two of the most common disease manifestations leading to digital and/or toe pain in systemic sclerosis (SSc).
- Trial name
- SScPF (NCT05234671)
- Testing
- Exercise programme
- Where
- United Kingdom
- Volunteers
- 170 people
- Sponsor
- Sheffield Hallam University
Multiple Sclerosis, Fatigue
The Effect of the Nurses Support Program on Fatigue in MS Patient
The research will be carried out as a randomized controlled experimental study to examine the effect of a nursing support program supported by a Web-based education program on the management of fatigue symptoms of patients who…
- Conditions
- Multiple Sclerosis, Fatigue, Sleep Hygiene, Quality of Life
- Trial name
- NCT06166043
- Testing
- NURSE FOLLOW-UP PROGRAM SUPPORTED WITH WEB-BASED EDUCATION
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul University - Cerrahpasa
Multiple Sclerosis
Mesenchymal Stem Cells for Multiple Sclerosis
The aim of the study is to evaluate the safety and efficacy of autologous mesenchymal stromal cells as treatment for Multiple Sclerosis.
- Trial name
- NCT01730547
- Testing
- Autologous mesenchymal stem cells
- Where
- Sweden
- Volunteers
- 2 people
- Sponsor
- Karolinska Institutet
Multiple Sclerosis
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
The primary objective is to determine whether prolonged-release fampridine (10 mg twice daily) has a clinically meaningful effect on participant-reported walking ability over a 24-week study period.
- Trial name
- ENHANCE (NCT02219932)
- Testing
- fampridine
- Where
- 87 sites in United States, Bulgaria and 9 more
- Volunteers
- 646 people
- Sponsor
- Biogen
Multiple Sclerosis
Functional Electrical Stimulation Cycling for Managing Mobility Disability in People with Multiple Sclerosis
Mobility impairment is one of the most common, poorly managed, and life altering consequences of MS. Current therapies for managing MS do not prevent the long-term accumulation of mobility impairment, highlighting the need for…
- Trial name
- NCT03949387
- Testing
- FES Cycling Exercise, Passive Leg Cycling
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of Ottawa
Asthma, Atrial Fibrillation
The Living With a Long-Term Condition Study
Psychological distress (anxiety and depression) is common in and experienced differently by people living with long-term health conditions (LTCs).
- Conditions
- Asthma, Atrial Fibrillation, Cancer, Cerebrovascular Disorders
- Trial name
- LTC (NCT06072287)
- Testing
- Living with LTC Questionnaire
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- King's College London
Multiple Sclerosis
Resilience in Young Adults Newly Diagnosed With Multiple Sclerosis
This study aims to fill the gap of knowledge on the biopsychosocial (BPS) characteristics and resilience of young adults newly diagnosed with Multiple Sclerosis, to evaluate the relationship among these variables, and to develop…
- Trial name
- BPS-ARMS (NCT03825055)
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Universita di Verona
Multiple Sclerosis, Rehabilitation
Functional Disorders of the Musculoskeletal System in People With Multiple Sclerosis
The randomized controlled trial is aimed to study the efficacy of treatment approaches based on developmental kinesiology models and its impact on balance, gait and mobility in people with mild to severe multiple sclerosis…
- Conditions
- Multiple Sclerosis, Rehabilitation, Musculoskeletal Complication
- Trial name
- NCT04973501
- Testing
- Manual physiotherapeutic correction (MFK) Method, Dynamic Neuromuscular Stabilization (DNS) Method
- Volunteers
- 50 people
- Sponsor
- Charles University, Czech Republic
Optic Neuritis, Neuromyelitis Optica
Optic Neuritis Differential Diagnosis Study
Background: Optic neuritis is a frequent cause of vision loss encountered by ophthalmologists in the Caribbean. The diagnosis is made on clinical grounds.
- Conditions
- Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis
- Trial name
- ONDDS (NCT03370965)
- Testing
- Neuro-ophtalmology examination
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital Center of Martinique
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
This is an exploratory, open-label, single-arm clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219CX.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07586267
- Testing
- QT-219CX
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Multiple Sclerosis, Chronic Progressive, Nervous System Diseases
Intrathecal Rituximab in Progressive Multiple Sclerosis
The goal of investigators is to study the kinetics of action of a single dose of intrathecally-infused rituximab upon cerebro-spinal fluid (CSF) biological targets in progressive MS patients.
- Trial name
- EFFRITE (NCT02545959)
- Testing
- Rituximab IT, methylprednisolone IV, Rituximab IV
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier de PAU
Active Secondary Progressive Multiple Sclerosis
Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
This is an observational, multicenter, single-arm, prospective study conducted in Italy
- Trial name
- ITASIA (NCT05376579)
- Testing
- siponimod
- Where
- 24 sites in Italy
- Volunteers
- 134 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy
The primary objective of the study is to investigate whether topical Vitamin K application reduces the grade of erythema in comparison with a vehicle cream (placebo) through physicians' assessment and participant self-assessment.
- Trial name
- VITALITY (NCT03091569)
- Testing
- Vitamin K Cream
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
The study will evaluate the effectiveness and safety of the investigational drug SB683699 in treating patients with relapsing multiple sclerosis (MS), using data from magnetic resonance imaging (MRI) scans as the main measure.
- Trial name
- NCT00097331
- Testing
- SB683699
- Where
- 11 sites in Belgium, Germany and 3 more
- Volunteers
- 261 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Tecfidera Slow-Titration Study
The primary objective of the study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the incidence of dimethyl fumarate (DMF [Tecfidera])-related gastrointestinal (GI) adverse…
- Trial name
- TITRATION (NCT02428231)
- Testing
- dimethyl fumarate
- Where
- 20 sites in United States, Belgium and 2 more
- Volunteers
- 62 people
- Sponsor
- Biogen
Multiple Sclerosis
NOGO-A in Multiple Sclerosis FTIH
The drug being tested in this study is GSK1223249. The drug works by inhibiting a protein that prevents nerve growth. The trial is expected to involve approximately 36 patients.
- Trial name
- NCT01424423
- Testing
- GSK1223249
- Where
- Australia
- Volunteers
- 3 people
- Sponsor
- GlaxoSmithKline
Relapsing Remitting Multiple Sclerosis
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
This study was to find out if patients with Relapsing Remitting Multiple Sclerosis treated with Interferon beta-1a had an improved quality of life after treatment with Interferon beta-1a
- Trial name
- FLAIR (NCT00534261)
- Testing
- Interferon beta-1a
- Where
- 3 sites in Belgium, Luxembourg and 1 more
- Volunteers
- 284 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting, Pain, Chronic
The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial
Even though, current treatments including IVIG, corticosteroids, biological agents can provide positive effects on MS symptoms, MS cannot be cured completely today.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Pain, Chronic, Fatigue Syndrome, Chronic, Kinesiophobia
- Trial name
- NCT04833673
- Testing
- PMR: Progressive Muscle Relaxation, BRT:Benson Relaxation Technique
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Hacettepe University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.